First Trust Advisors LP lessened its stake in Novartis AG (NYSE:NVS) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 232,423 shares of the company’s stock after selling 1,022 shares during the period. First Trust Advisors LP’s holdings in Novartis AG were worth $19,954,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new stake in Novartis AG during the 2nd quarter worth $241,000. Bartlett & Co. LLC raised its stake in Novartis AG by 1.6% during the 3rd quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock worth $40,614,000 after acquiring an additional 7,249 shares during the period. Westwood Holdings Group Inc. raised its stake in Novartis AG by 5.6% during the 1st quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock worth $401,000 after acquiring an additional 285 shares during the period. GFS Advisors LLC raised its stake in Novartis AG by 6.5% during the 2nd quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock worth $1,779,000 after acquiring an additional 1,300 shares during the period. Finally, Schafer Cullen Capital Management Inc. raised its stake in Novartis AG by 9.2% during the 2nd quarter. Schafer Cullen Capital Management Inc. now owns 2,780,606 shares of the company’s stock worth $232,097,000 after acquiring an additional 233,292 shares during the period. 10.94% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Novartis AG (NVS) Shares Sold by First Trust Advisors LP” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/novartis-ag-nvs-shares-sold-by-first-trust-advisors-lp/1680399.html.

Novartis AG (NYSE NVS) opened at $83.70 on Friday. Novartis AG has a fifty-two week low of $66.93 and a fifty-two week high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The firm has a market cap of $198,000.30, a price-to-earnings ratio of 17.62, a P/E/G ratio of 2.67 and a beta of 0.72.

Novartis AG (NYSE:NVS) last posted its earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. The firm had revenue of $12.41 billion during the quarter, compared to analyst estimates of $12.21 billion. Novartis AG had a net margin of 13.73% and a return on equity of 15.77%. Novartis AG’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the firm posted $1.23 earnings per share. research analysts predict that Novartis AG will post 4.75 EPS for the current year.

A number of equities research analysts have commented on the stock. J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, October 31st. Zacks Investment Research upgraded shares of Novartis AG from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Barclays PLC cut shares of Novartis AG from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, Leerink Swann lifted their price objective on shares of Novartis AG from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company’s stock. Novartis AG currently has a consensus rating of “Hold” and an average target price of $85.28.

Novartis AG Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.